Physician profile
Deepak Rao
NPI 1215090808
$3,683.59
in general payments reported to CMS, 2019-2025
21 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,692 · 2020: $561 · 2021: $98.36 · 2022: $81.53 · 2023: $103 · 2024: $22.76 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $250.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $622.24 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $474.73 | 2019-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $466.68 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $305.83 | 2019-2020 | |
| Lundbeck LLC | $295.84 | 2019-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $273.93 | 2019-2025 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $230.50 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $140.40 | 2019-2020 | |
| Shire North American Group INC | $125.66 | 2019 | |
| Tris Pharma INC | $121.60 | 2019 | |
| Abbvie INC. | $121.12 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $93.63 | 2019-2025 | |
| Alkermes, INC. | $77.34 | 2019-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $73.32 | 2019 | |
| Neuronetics, INC. | $66.74 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $59.41 | 2019-2023 | Perseris |
| Bausch Health US, LLC | $46.03 | 2019-2023 | Aplenzin |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.35 | 2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $24.97 | 2025 | Jornay Pm |
| Neos Therapeutics, Lp | $20.27 | 2019 | |
| Adlon Therapeutics L.P. | $16.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.